Insider Trading Activity Coherus BioSciences, Inc. (NASDAQ:CHRS) – Insider Sold 17,535 shares of Stock

ME Staff
-
0

Insider Trading Activity For Coherus BioSciences, Inc. (NASDAQ:CHRS)

Alan C Herman , Insider of Coherus BioSciences, Inc. (NASDAQ:CHRS) reportedly Sold 17,535 shares of the company’s stock at an average price of 15.02 for a total transaction amount of $263,375.70 SEC Form

Insider Trading History For Coherus BioSciences, Inc. (NASDAQ:CHRS)

  • On 11/12/2014 Eli & Co Lilly, Insider, bought 164,963 with an average share price of $13.50 per share and the total transaction amounting to $2,227,000.50.View SEC Filing
  • On 6/15/2015 August J Troendle, Director, sold 250,000 with an average share price of $26.68 per share and the total transaction amounting to $6,670,000.00.View SEC Filing
  • On 8/14/2015 Mats Wahlstrom, Director, sold 116,554 with an average share price of $34.24 per share and the total transaction amounting to $3,990,808.96.View SEC Filing
  • On 8/17/2015 Mats Wahlstrom, Director, sold 8,028 with an average share price of $33.91 per share and the total transaction amounting to $272,229.48.View SEC Filing
  • On 8/18/2015 Mats Wahlstrom, Director, sold 6,373 with an average share price of $33.50 per share and the total transaction amounting to $213,495.50.View SEC Filing
  • On 9/1/2015 Alan C. Herman, insider, sold 11,333 with an average share price of $27.39 per share and the total transaction amounting to $310,410.87.View SEC Filing
  • On 10/1/2015 Alan C. Herman, insider, sold 4,250 with an average share price of $18.98 per share and the total transaction amounting to $80,665.00.View SEC Filing

    • Analyst Ratings For Coherus BioSciences, Inc. (NASDAQ:CHRS)
    These are 9 Buy Ratings .
    The current consensus rating for Coherus BioSciences, Inc. (NASDAQ:CHRS) is Buy (Score: 3.00) with a consensus target price of $37.00 , a potential (221.04% upside)

    Analyst Ratings History For Coherus BioSciences, Inc. (NASDAQ:CHRS)

    • On 11/25/2016 Standpoint Research Initiated Coverage of rating Buy with a price target of $40.00
    • On 5/21/2017 Barclays PLC Reiterated Rating Overweight with a price target of $46.00
    • On 6/12/2017 Maxim Group Lower Price Target of rating Buy to Buy with a price target of $44.00 to $40.00
    • On 6/13/2017 Robert W. Baird Lower Price Target of rating Outperform with a price target of $40.00 to $37.00
    • On 6/13/2017 BMO Capital Markets Lower Price Target of rating Outperform with a price target of $54.00 to $43.00
    • On 6/13/2017 Cowen and Company Reiterated Rating Outperform with a price target of $45.00
    • On 6/13/2017 Citigroup Inc Lower Price Target of rating Buy with a price target of $38.00 to $33.00

    Recent Trading Activity for Coherus BioSciences, Inc. (NASDAQ:CHRS)
    Shares of Coherus BioSciences, Inc. closed the previous trading session at 11.52 down -1.08 -8.53% with 617,815 shares trading hands.